Minhua Chu
@chuminhua432
BD & transaction service, marketing strategy, focus on Chinese healthcare industry
🇨🇳 #China Biopharma Tracker H1 2025 #biopharma #biotech #MHTracker New Drug Approvals: x.com/chuminhua432/s… Licensing Deals: x.com/chuminhua432/s… Financing: github.com/chuminhua/Minh… #financing 1/ In the first half of 2025, private biopharma companies in China…
1/ #China Biopharma Licensing Deals H1 2025 github.com/chuminhua/Minh… #biopharma #license #deal #MHTracker In the first half of 2025, Chinese biopharma companies announced 66 licensing deals, with total upfront payments of $2.7 billion and potential milestone payments reaching…
🇨🇳 #AusperBio announced that China #NMPA has cleared a Phase 3 clinical trial application for their lead candidate, AHB-137. AHB-137 is a non-conjugated antisense oligonucleotide (#ASO) drug with the potential to serve as a cornerstone for achieving a clinical cure for CHB.…
Eisai #China announced that #lenvatinib has been approved by 🇨🇳#NMPA for use in combination with pembrolizumab and transarterial chemoembolization (TACE) for the treatment of patients with unresectable non-metastatic hepatocellular carcinoma. In September 2018, lenvatinib was…
🇨🇳 #NMPA has approved the marketing application of tunodafil, a PDE5 inhibitor submitted by Yangtze River Pharma, for the treatment of erectile dysfunction. On February 25, 2023, Yangtze River Pharmaceutical submitted the marketing application and was accepted. The drug was…
🇨🇳#Newish Tech announced the completion of a Series B1 funding, raising tens of millions of RMB. This round was jointly invested by Botong Capital, Wuxi Innovation Investment, and Shandong Meijia Group, with the funds primarily used to advance clinical Phase I and II studies of…
🇨🇳 Nanjing Leads Biolabs listed on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) under the stock code "09887". prnewswire.com/news-releases/… priced its IPO at HKD 35 per share, offering 36.86 million shares (excluding green shoe option). Gross proceeds totaled…
🇨🇳 Zonsen PepLib Biotech announced the completion of nearly RMB 100 million in Series B financing led by . This marks the third round of equity financing for Zonsen, following its Series A and Series A+ in December 2019 and April 2021, respectively. The Series B round was led…
🇨🇳 Shanghai-based Cascade Pharannounced that its CS0159 tablet, for the treatment of primary biliary cholangitis (PBC) has received Breakthrough Therapy Designation from the FDA. Previously, the product had already obtained FDA Fast Track designation for MASH and Orphan Drug…
🇨🇳 Kelun-Biotech has registered a Phase I clinical trial (SKB107-I-01) in China to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and efficacy of #SKB107 in patients with advanced solid tumor bone metastases. SKB107 is a radionuclide conjugate drug…
🇨🇳 #Qilu Pharma has registered a Phase III clinical trial (NCT07079228) clinicaltrials.gov/study/NCT07079… for its CLDN18.2/CD3 bispecific antibody #QLS31905, + nab-paclitaxel + gemcitabine chemotherapy, in patients with CLDN18.2-positive advanced pancreatic cancer receiving first-line…
A peak at CAR-T therapies in the #autoimmune #inflammation landscape (+ bispecifics)
Ten years ago today, on July 22, 2015, 🇨🇳 #NMPA issued Announcement No. 117, titled "Notice on Conducting Self-Inspection and Verification of Clinical Trial Data," which shook the industry’s longstanding issues. A total of 1,622 clinical trial projects were required to undergo…
🇨🇳 DualityBio announced that FDA has granted Fast Track Designation (FTD) to its next-generation #HER3-targeting #ADC DB-1310. This designation is for the treatment of adult patients with advanced, unresectable or metastatic nonsquamous non-small cell lung cancer (nsqNSCLC) with…
🇨🇳 Simcere Zaiming, the oncology subsidiary of Simcere Pharmaceutical, announced that the IND application for its independently developed FGFR2b-targeted #ADC, SIM0686, has recently been approved by the U.S. FDA. SIM0686 is a clinical-stage ADC project developed using Simcere…
🇨🇳 Novatim Immune Therapeutics signed an exclusive licensing agreement with U.S.-based biopharma ERIGEN LLC. for KQ-2003, dual-target CAR-T cell therapy developed in-house by Novatim, which targets BCMA and CD19. The agreement grants ERIGEN exclusive rights to develop,…
1/Here’s an excellent Financial Times article which accurately describes the problematic situation which many big Pharma companies such as $PFE $JNJ $BMY $ABBV $LLY $MRK $SNY and others are now facing - the upcoming patent cliff scenario. With IP rights which are about to expire…